[1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115. doi: 10.3322/caac.21338
[2] SROLER MH, WRIGHT TC, FERENCZY A, et al. Routine use of adjunctive p16 immunohistochemistry improves diagnostic agreement of cervical biopsy interpretation: results from the certain study[J]. Am J Surg Pathol, 2018, 42(8): 1001. doi: 10.1097/PAS.0000000000001072
[3] MARC B, JANE JK, KAREN C, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries[J]. Lancet, 2020, 395(10224): 575. doi: 10.1016/S0140-6736(20)30068-4
[4] CAROZZI F, GILLIO-TOS A, CONFORTINI M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial[J]. Lancet Oncol, 2013, 14(2): 168. doi: 10.1016/S1470-2045(12)70529-6
[5] YU LL, CHEN W, LEI XQ, et al. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China[J]. Oncotarget, 2016, 7(16): 21181. doi: 10.18632/oncotarget.8307
[6] KHLEIF SN, DEGREGORI J, YEE CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclinkinase inhibitor activity[J]. Proc Natl Acad Sci USA, 1996, 93(9): 4350. doi: 10.1073/pnas.93.9.4350
[7] PAUCK A, LENER B, HOELL M, et al. Depletion of the cdk Inhibitor p16INK4a differentially affects proliferation of established cervical carcinoma cells[J]. J Virol, 2014, 88(10): 5256. doi: 10.1128/JVI.03817-13
[8] PRIGENZI KCK, HEINKE T, SALIM RC, et al. Dual p16 and Ki-67 expression in liquid-based cervical cytological samples compared to pap cytology findings, biopsies, and hpv testing in cervical cancer screening: a diagnostic accuracy study[J]. Acta Cytol, 2018, 62(2): 104. doi: 10.1159/000487504
[9] WENTZENSEN N, CLARKE MA, BREMER R, et al. Clinical evaluation of human papillomavirus screening with p16/ki76 dual stain triage in a large organized cervical cancer screening program[J]. JAMA Intern Med, 2019, 179(7): 881. doi: 10.1001/jamainternmed.2019.0306
[10] MARIAM EZ, WALTER G, LUCY G, et al. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing (STAIN-IT) study[J]. Int J Cancer, 2021, 148(2): 492. doi: 10.1002/ijc.33250
[11] IKENBERG H, BERGERO C, SCHMIDT D, et al. Screening for cervical cancer precursors with p16/ki-67 dual-stained cytology: results of the PALMS study[J]. J Natl Cancer Inst, 2013, 105(20): 1550. doi: 10.1093/jnci/djt235
[12] 贾漫漫, 赵冬梅, 郭珍, 等. p16/Ki-67双染监测在高危型人乳头瘤病毒阳性人群中的分流效果评价[J]. 中华预防医学杂志, 2020, 54(2): 192. doi: 10.3760/cma.j.issn.0253-9624.2020.02.015
[13] ZHANG G, YANG B, ABDUL-KARIM FW, et al. P16 immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing[J]. Int J Gynecol Pathol, 2015, 34(2): 180. doi: 10.1097/PGP.0000000000000112
[14] SHAIN AF, KWOK S, FOLKINS AK, et al. Utility of p16 immunohistochemistry in evaluating negative cervical biopsies following high-risk pap test results[J]. Am J Surg Pathol, 2018, 42(1): 69. doi: 10.1097/PAS.0000000000000960
[15] SHAIN AF, WILBUR DC, STOLER MH, et al. Test characteristics of specific p16 clones in the detection of high-grade squamous intraepithelial lesions (HSIL)[J]. Int J Gynecol Pathol, 2018, 37(1): 82. doi: 10.1097/PGP.0000000000000391
[16] CUZICK J, ADCOCK R, CAROZZI F, et al. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening[J]. Int J Cancer, 2020, 147(7): 1864. doi: 10.1002/ijc.32973
[17] WU MZ, WANG S, ZHENG M, et al. The diagnostic utility of p16 immunostaining in differentiating cancer and HSIL from LSIL and benign in cervical cells[J]. Cell Transplant, 2019, 28(2): 195. doi: 10.1177/0963689718817478